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VIROLOGY
Short Communication: Antiretroviral Therapy Resistance
Mutations Present in the HIV Type 1 Subtype C pol
and env Regions from Therapy-Naive Patients in Zambia
Sandra Gonzalez,1* Clement Gondwe,2* Damien C. Tully,1 Veenu Minhas,1 Danielle Shea,1
Chipepo Kankasa,2 Tendai M’soka,2 and Charles Wood1
Abstract
The prevalence of antiretroviral therapy (ART) resistance mutations present in HIV-1 subtype C pol and env
regions of the proviral DNA was analyzed and compared from therapy-naive individuals before (Cohort A) and
after (Cohort B) the availability of free ART in Zambia. Mutations present in sequences published in a previous
study from Zambian ART-naive individuals infected with subtype C were analyzed using current parameters
for the classification of ART drug resistance and compared with Cohorts A and B. No statistically significant
differences were observed when comparing mutations present in the pol and env of these cohorts. However, an
increase in the number of minor, borderline, or partial resistance mutations as well as the presence of major
resistance mutations were observed in Cohort B. These results suggest there is an increasing trend of drug
resistance-associated mutations that could be a result of the availability of free ART in Zambia. Moreover, the
high prevalence of resistance mutations observed for maraviroc and vicriviroc in both cohorts may suggest a
limited efficacy of entry inhibitors on HIV-1 subtype C.
Of the 33 million people infected worldwide with thehuman immunodeficiency virus type 1 (HIV-1), almost
65% live in sub-Saharan Africa.1 High genetic variability and
rapid evolution are the two major factors that contribute to the
spread of HIV-1. The main cause of the high genetic hetero-
geneity, or quasispecies, is the low-fidelity and error-prone
reverse transcriptase of the virus. As a result of this continu-
ous divergence, several HIV-1 subtypes or clades have
emerged.2 In southern Africa, 98% of HIV-1 infections are
subtype C variants; it is the most prevalent subtype, ac-
counting for over 50% of the new infections globally.3
Antiretroviral therapy (ART) has been effective in de-
creasing morbidity and mortality in developed countries.4
Nevertheless, these regimens have only recently become
available in the developing world.5 As ART is rapidly scaled
up in Africa and other resource-limited countries, surveillance
of the prevalence of ART resistance-associated mutations is
necessary to ensure optimal therapy.6 In 2002 the Zambian
Ministry of Health initiated an ART program at the country’s
two largest hospitals, making treatment available to the
public sector.7 Access to ART was increased in 2004, when the
Zambian Ministry of Health initiated an ART program at
primary care sites within Lusaka (capital of Zambia), with
financial resources from the U.S. President’s Emergency Plan
for AIDS Relief (PEPFAR); the Global Fund to Fight AIDS,
Tuberculosis and Malaria; and other sources. The first line
treatment consists of a three-drug ART, lamivudine (3TC),
either nevirapine (NVP) or efavirenz (EFV), and either zido-
vudine (ZDV) or stavudine (d4T).7 Overall, the rapid scale-up
of ART has been associated with good clinical outcomes in
primary care settings in Zambia. However, mortality during
the first 90 days of therapy is high.7 Currently, the information
available on HIV-1 drug-resistant viruses in Zambia is lim-
ited, and whether there is transmission of drug-resistant
viruses is unclear. Moreover, due to the high prevalence of
HIV-1, the rapid scale-up of ART availability still benefits only
a portion of the infected individuals in Zambia. By 2009, the
National AIDS Council in Zambia (http://www.nac.org.zm)
reported that approximately 12% of the population (1.3 mil-
lion) is infected with HIV-1. Although 350,000 of these
HIV-infected individuals require treatment, only 180,000 had
access to free ART.
Therapy failure to reverse transcriptase (RT), and protease
(PR) inhibitors is mainly caused by mutations in the pol gene.
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Significant genotypic and phenotypic differences between
different HIV-1 subtypes have been observed in drug-
resistant variants isolated from both ART-naive and ART-
treated patients. Studies have shown a higher prevalence of
naturally occurring ART-resistant subtype C variants in the
pol gene of ART-naive patients in southern Africa.8,9 There is
also a higher prevalence of NVP-resistant subtype C strains
than other subtypes.2 Moreover, some of these naturally oc-
curring polymorphisms likely accelerate the emergence of
ART resistance.10 In addition to mutations in the pol gene,
drug resistance-associated mutations (DRAMs) have also
been recently reported in the V3 region of the env against the
CCR5 entry inhibitors maraviroc11 and vicriviroc.12 Because
drug resistance and resistance-associated mutations may
have a profound impact on the clinical management of pa-
tients, surveillance of ART resistance in both treated and un-
treated individuals is essential for the development and
implementation of an effective therapy.
The objective of the current study was to determine the
effect of the scale-up of ART in Zambia on ART resistance-
associated polymorphisms and drug-resistant mutations. To
achieve this goal we analyzed and compared the prevalence
of ART resistance mutations in the pol and env of proviral
DNA from subjects in two cohorts collected before and after
ART was freely available in Zambia. All subjects were HIV-1-
positive adults infected with subtype C who were ART naive
at the time of sample collection. A written informed consent
was obtained from all participants and the study was ap-
proved by the Institutional Review Boards of the University of
Nebraska and University of Zambia. Cohort A, comprising 32
samples collected before the availability of ART, was ran-
domly selected from archived frozen peripheral blood
mononuclear cells (PBMCs) from ART-naive HIV-1þ Zam-
bian women obtained between 1998 and 2002 in Lusaka,
Zambia. These women were participants of a mother–infant
pairs cohort and were diagnosed as HIVþ at the time of de-
livery. The average age of the women in Cohort A was 26.06
years (range, 18–40 years). In addition to being recently di-
agnosed as HIV seropositive, these women were ART therapy
naive and had no evidence of HIV/AIDS-related opportu-
nistic infection on physical examination. Furthermore, all
patients resided within Lusaka and were able to give in-
formed consent. Twenty-six of these samples were collected at
the time of delivery (baseline). Due to the low HIV DNA copy
number and the difficulty in obtaining a polymerase chain
reaction (PCR) product for the baseline time point, a sample
from a subsequent time point was analyzed for six individuals
included in Cohort A.
Cohort B was composed of 90 samples randomly selected
from a surveillance study during 2005 for HIV-1 subtyping
and genotyping, and all samples were from HIV-1þ ART-
naive adults recruited at the Voluntary Counseling and
Testing (VCT) centers. This cohort was composed of 57 fe-
males, 29 males, and 4 unknowns with an average age of 33.09
years (range, 20–63). These individuals were able to provide
an informed consent and had no reported evidence of HIV/
AIDS opportunistic infections at the time the sample was
collected. No other clinical information from these individuals
was collected. The specimens were collected from various
VCT sites located in 15 different towns distributed throughout
Zambia. These towns, strategically chosen to represent the
Zambian population, included Chirundu, Chipata, Kasama,
Kasumbalesa, Kapiri Mposhi, Kitwe, Kawambwa, Kazungu-
la, Lusaka (Chawama and Kanyama area), Livingstone,
Ndola, Mansa, Maheba, Mongu, and Solwezi. All 122 samples
were analyzed for mutations in the pol PR and RT and the V3
region of the env by direct sequencing.
Due to the difficulties associated with the transport and
storage of plasma viral RNA, ART resistance was analyzed
from DNA extracted from PBMCs. Although it is known that
PBMC samples may include information about archived viral
mutations, it has recently been shown that the rates of de-
tection of ART mutations in plasma RNA are similar to those
observed in proviral DNA from PBMC samples.13 For both
cohorts PBMCs were isolated on site from 2 ml to 5 ml of
whole blood treated with ethylenediamine tetraacetic acid
(EDTA) followed by a Ficol/Hypaque density centrifugation.
The isolated cells were resuspended in 1 ml of phosphate-
buffered solution (PBS). DNA extraction from Cohort A
PBMC samples was done at the Nebraska Center for Virology
using the Gentra Puregene Cell kit (QIAGEN, Valencia, CA)
following the manufacturer’s indications. DNA extraction
from Cohort B PBMCs was performed at the University
Teaching Hospital Virology Laboratory in Lusaka, Zambia,
using the QIAamp DNA Extraction kit (QIAGEN, Valencia,
CA) following the manufacturer’s recommended procedure.
The extracted DNA was suspended in 100% ethanol and then
stored at 808C for further experimental work.
The C2V4 region of the proviral DNA env was amplified by
seminested PCR and sequenced following the conditions
previously reported.14 The subtype was determined by
neighbor-joining phylogenetic analysis that included group
M reference consensus sequences from the Los Alamos HIV
Sequence Database and confirmed by reanalyzing the C2V4
sequences using the REGA HIV subtyping tool from HIV
Bioinformatics Bioafrica.15 The C2V4 env region was suc-
cessfully amplified for 28 of the 32 samples in Cohort A. Of
those 28 env sequences, 26 (92.8%) were subtype C. One of
these non-subtype C sequences clustered with subtype H.
However, due to the short length of the latter env sequence
this subtype was not assigned as a pure subtype. The analysis
also identified the remaining sequence as an AC recombinant
with significant clustering (>70%) observed with subtypes A
and C, respectively.
Sequences from Cohort B C2V4 were obtained for 81 of the
90 samples. Seventy-nine (98%) of these sequences were
confirmed as subtype C. The REGA HIV subtyping tool
classified one of these sequences as subtype A1. No subtype
was assigned to the second non-subtype C sequence because
no significant clustering was observed with a pure subtype.
Results were further corroborated by a neighbor-joining
phylogenetic analysis comprising C2V4 subtype C sequences
from both cohorts and the most recent (2008) group M HIV-1
reference sequences from the Los Alamos HIV Sequence Da-
tabase (Fig. 1A). These results confirm that HIV-1 subtype C is
the predominant subtype circulating in Zambia. Only subtype
C sequences were included in the analysis of entry inhibitor
resistance mutations.
For the analysis of ART mutations in the pol gene, a 1493-bp
region of the gag-pol gene including the sequence encoding the
Gag protein p7 C terminus, p1, and p6 (Gag codons 406–500),
full-length protease, and the first 314 amino acids of RT were
amplified by nested PCR using the primers published by
Zhang et al.16 The HiFi Hot star high fidelity polymerase
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(QIAGEN, Valencia, CA) was used to amplify the pol region.
For the thermal cycling conditions, an initial 958C for 5 min
denaturing step was followed by 30 cycles of 948C for 15 s,
508C for 1 min, and 728C for 2 min and a final extension of
728C for 10 min. The size of the amplified PCR products was
confirmed by electrophoresis in a 1.5% agarose gel. The pos-
itive PCR products were then purified using the E.Z.N.A. Gel
Extraction Kit (Omega Bio-Tech, Norcross, GA). The concen-
tration of the final purified PCR products was determined
using the NanoDrop ND-1000 spectrophotometer (Thermo
Scientific, NanoDrop products Wilmington, DE).
The direct sequencing reaction of the pol region was per-
formed from 20–40 ng of template using seven primers (Table
1) and the BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA) following the manu-
facturer’s protocol for PCR and precipitation of sequencing
reactions. Sequencing of the pol and env genes was done using
the ABI PRISM 3100-Avant Genetic Analyzer (Applied Bio-
systems, Foster City, CA). The seven partially overlapping
sequences were assembled and aligned by using the BioEdit
7.0.9 software.17 Resistance-associated mutation analyses
based on the Stanford Drug Resistance Database (SDRD),
2009 and the International AIDS Society-USA (IAS-USA) 2007
drug resistance mutation list were generated using the Stan-
ford Drug Resistance Database Calibrated Population Re-
sistance (CPR) tool (http://surveillance.stanford.edu/cpr/
index.html). Moreover, the IAS-USA 2008 spring update of
drug resistance mutations was also referenced to perform this
analysis.18 The subtype from pol sequences was determined
using the subtype analyzer (STAR) application19 of the CPR
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FIG. 1. Phylogenetic analysis of ART-naive individuals infected with HIV subtype C. Nucleotide sequences from the pol (A)
and env (B) regions were aligned for all therapy-naive individuals infected with subtype C in conjunction with HIV-1 Group
M reference sequences. Each set of reference sequences for a specific subtype is represented by a letter indicating the subtype.
Subtype C reference sequences are also identified by solid squares. The scale bar in the unrooted neighbor-joining tree
represents 2% evolutionary distance per position in the sequence.
Table 1. Sequencing Primers for the Detection of DRAMs in the pol and env Genes of HIV Subtype C
Position-in HXB2 Orientation Sequence
Protease and reverse transcriptase regions of pol
2066? 2096 Sense 50-gTACTgAgAgACAggCTAATTTTTTAgggAA-30a
2219? 2247 Antisense 30-TTAAgggTTCCCTgTCTTTCggCT-50
2486? 2509 Sense 50-ACCTACACCTgTCAACATAATTgg-30b
2582? 2605 Antisense 30-gggCCATCCATTCCTggCTTTAAT-50
3001? 3024 Sense 50-AgggATggAAAggATCACCAgCAA-30
3001? 3024 Antisense 30-TTgCTggTgATCCTTTCCATCCCT-50
3345? 3371 Antisense 30-AATCCCTgCATAAATCTgACTTgCCCA-50a
C2V4 Region of env
6882? 6904 Sense 50-CCTgCTggTTATgCgATTCTAAA-30c
7378? 7350 Antisense 30-CAATAgAAAAATTCTCCTCTACAATTAAA-50c
aCai et al.30
bZhang et al.16
cZhang et al.14
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tool and confirmed with the REGA HIV subtyping tool from
HIV Bioinformatics Bioafrica.15 As described above for env,
most of the pol sequences were classified as subtype C by the
REGA HIV subtyping tool, although other subtypes
were observed in both cohorts. In Cohort A, 97% of the pol
sequences were subtype C with a single sequence identi-
fied as an AC recombinant. Likewise, in Cohort B, most of
the pol sequences were classified as subtype C (98%) and
only two of the 90 sequences were designated as non-subtype
C (2%). One of these non-subtype C pol sequences was an AG
recombinant, as confirmed by significant bootstrapping
with both subtypes. The remaining sequence was identified as
a complex mosaic recombinant in which a number of different
subtypes were identified, although with low bootstrap
confidence. Results for the subtyping analysis were also
confirmed by a neighbor-joining phylogenetic analysis com-
prising pol subtype C sequences from both cohorts and the
most recent (2008) group M HIV-1 reference sequences
from the Los Alamos HIV Sequence Database (Fig. 1B). Only
those sequences classified as subtype C were included in the
PR and RT inhibitors genotyping analysis. The prevalence of
each mutation was analyzed and also compared between
cohorts by a nonparametric Fisher’s exact test and a p value
0.05 was considered significant. This analysis was per-
formed using the statistical software package SPSS version 17
(SPSS, Chicago, IL).
Hypermutated sequences, one from Cohort A and two
from Cohort B, were excluded from the analysis to eliminate
potential genotypic errors.20 After this elimination, a total of
30 sequences from Cohort A and 86 sequences from Cohort B
were analyzed for genotyping of PR and RT. In summary,
borderline (SDRD) and minor mutations (IAS-USA) were
observed in both cohorts (Table 2) and major mutations were
observed only in Cohort B (Table 3). The minor and borderline
resistance mutations present in both cohorts are shown in
Table 2. For comparison we have also included the ART minor
mutations reported by another study conducted during 2000
in Zambia (referred to as the Handema et al. cohort).8 To be
consistent in the parameters used for the analysis, PR and
RT sequences published in this study (GenBank accession
numbers AB081151–AB081175 for protease and AB081176–
AB081203 for reverse transcriptase) were analyzed using
current drug resistance classification parameters. The preva-
lence range of the three PR resistance-associated mutations,
M36I, H69K, and I93L, was 80–100% in all the three cohorts.
These mutations were also present in the subtype C consensus
sequence; hence, they were considered to be natural poly-
morphisms and were excluded from the analysis. After
eliminating these three mutations, a total of nine borderline/
minor mutations were detected in Cohort A (prevalence range
3–20 %) and 14 in Cohort B (prevalence range 1–21%). These
findings contrast with data reported for Zambia by Handema
Table 2. Prevalence of Minor and Borderline ART Mutations Associated with Resistance to PIs
and RTIs in Both Cohorts and Compared with Published Data
Observed prevalence for each resistance mutation (%)
Handema et al.,8 2000
(N¼ 25)
Cohort A, 1998–2002
(N¼ 30)
Cohort B, 2005
(N¼ 66) Comparison of prevalence between cohorts, pa
Mutation Class
SDRM
(2009)
IAS-USA
(2007)b
SDRM
(2009)
IAS-USA
(2007)b
SDRM
(2009)
IAS-USA
(2007)b
Handema to
Cohort A
Handema to
Cohort B
Cohort A to
Cohort B
Protease region
L10V PI —c 0 — 3.33 — 0 1.000 N.O. 0.2586
I13V PI — 4.2 — 0 — 0 0.455 0.2252 N.O.
G16E PI — 20 — 3.33 — 8.14 0.082 0.1372 0.6781
K20R PI — 4 — 20 — 20.93 0.112 0.0679 1.0000
K20M PI — 0 — 0 — 1.16 N.O.d 1.0000 1.0000
L33F PI — 0 — 0 — 0 N.O. N.O. N.O.
M36L PI — 4 — 6.67 — 2.33 1.000 1.0000 0.2746
M36V PI — 4 — 0 — 1.16 0.455 0.4013 1.0000
Q58E PI — 0 — 0 — 1.16 N.O. 1.0000 1.0000
D60E PI — 4 — 10 — 12.79 0.617 0.2922 1.0000
I62V PI — 0 — 0 — 4.65 N.O. 0.5728 0.5712
L63P PI — 20 — 13.33 — 20.93 0.716 1.0000 0.4292
I64V PI — 4 — 0 — 0 0.455 0.2252 N.O.
I64L PI — 4 — 0 — 0 0.455 0.2252 N.O.
A71T PI — 0 — 3.33 — 1.16 1.000 1.0000 0.4520
V77I PI — 0 — 3.33 — 5.81 1.000 0.5858 1.0000
V82I PI — 0 — 10 — 3.49 0.242 1.0000 0.1781
Reverse transcriptase region
T69S NRTI 0 — 0 — 1.16 — N.O. 1.000 1.0000
V90I NNRTI — 0 — 0 — 3.49 N.O. 1.000 0.5674
V179D NNRTI 0 0 0 0 1.16 1.16 N.O. 1.000 1.0000
D218E NRTI 0 — 0 — 1.16 — N.O. 1.000 1.0000
ap values from the Fisher’s exact test were used to compare the prevalence of mutations between cohorts.
bIAS-USA (2007) report was updated with mutations that were identified in the IAS-USA 2008 Spring report (L10V, I13V, and L33F).
c—, No DRAM was designated for the respective position.
dN.O., no observations.
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et al., in which only seven minor mutations (prevalence range
4–17%) were observed.8 The lower prevalence of mutations
compared to our 1998–2002 cohort could be due to the use of
different methods by the authors for the classification of ART
resistance-associated mutations when the study was pub-
lished.8 In the current study we analyzed our data following
both the 2008 and 2009 SDRD classification parameters. In
fact, when these parameters were used to reanalyze sequences
published by Handema et al., nine borderline mutations
(prevalence range 4–20%) were detected as seen with our
Cohort A. In addition, according to the SDRD 2009 analysis,
no PR major mutations were observed in either cohort or the
sequences published by Handema et al. However, the PR
mutation Q58E, which is considered a borderline mutation by
the SDRD 2009, was classified as a major mutation in the
SDRD 2008. This mutation was observed only in Cohort B
(Table 3). Thus, methods of analysis could affect the inter-
pretation of mutations and a consistent method of analysis
needs to be used.
No mutations were observed for the RT region in either
Cohort A or the Handema et al. cohort; however, six DRAMs
(three NRTIs and three NNRTIs) were present in Cohort B.
Two of these were the major mutations (K103N, NNRTI and
M184V, NRTI) and were observed in 1% of the samples. The
remaining four mutations (T69S, V90I, V179D, and D218E)
were minor or borderline/suspicious and were observed in 1–
3% of the samples (Table 2). The prevalence of each mutation
was also compared between cohorts. For minor and border-
line mutations, no statistically significant differences were
observed between published results by Handema et al. to
Cohort A and to Cohort B or between Cohort A and Cohort B
(Table 2). In addition, a trend toward an increase in the
number of DRAMs was observed in the 2005 cohort; however,
it was not statistically significant. Similar results were ob-
served when comparing the observed prevalence of each
primary mutation between Cohort A and Cohort B (Table 3).
The similarity of DRAM frequencies may indicate that some
of these mutations are natural polymorphisms for HIV-1
subtype C in Zambia. The lack of significant differences be-
tween cohorts may also be explained by the low percentage of
HIV-infected individuals undergoing ART treatment in
Zambia in 2005. Although primary mutations were observed
in Cohort B, the low prevalence of these mutations reflects a
low percentage of transmission of drug resistance after the
availability of free ART in Zambia. However, PIs are not in-
cluded in the first line treatment offered through Zambia’s
free ART program, and we suggest that the mutations ob-
served in our cohort are naturally occurring polymorphisms
that may have increased in prevalence due to transmission.
Although borderline and minor mutations alone do not sig-
nificantly increase the level of resistance, when combined
with other mutations, they can increase the resistance to in-
hibitors by influencing the enzyme’s catalytic efficiency.10
Thus, these mutations should be monitored. This surveillance
is also important as a prevalence higher than 15% of ART
mutations within a population could have negative implica-
tions on treatment efficacy.21
We have also analyzed the env V3 loop sequences isolated
from subjects in our cohorts and the Handema et al. study,
even though entry inhibitors are not currently included in the
ART therapy available in Zambia. It is important to determine
whether there are any natural polymorphisms in this region
that may compromise the use of this treatment strategy in the
future. Mutations associated with resistance to the CCR5 an-
tagonists maraviroc and vicriviroc were included in the
analysis because maraviroc is already an FDA-approved drug
and vicriviroc is currently in phase three clinical trials,22
mostly with subtype B virus-infected individuals.23,24 Because
it is known that about 50% of the patients infected with sub-
type B virus develop X4 tropic viruses at later stages of in-
fection,25,26 it is not surprising that viruses resistant to these
drugs have already been observed by switching their co-
receptor usage from R5 to X4.23,24 In contrast to subtype B,
subtype C is mainly an R5 tropic virus,22 with very few
CXCR4 or dual tropic viruses reported.27 Therefore, the use of
these compounds could significantly improve the therapy
outcome of individuals infected with subtype C viruses if no
DRAMs are present. However, the susceptibility and the de-
velopment of resistance to these inhibitors by subtype C
viruses are not known.12 For maraviroc, the mutations A316T
and I323V have been reported to confer partial resistance for
subtype B viruses. Complete resistance to this entry inhibitor
occurs when both mutations (A316T/I323V) are present.11
Surprisingly, some of these mutations were already present in
the subtype C env sequences from both of our cohorts as well
as in the cohort analyzed by Handema et al. in 2000. The
prevalence of resistance-associated mutations to entry inhib-
itors is shown in Table 4. The mutation A316T was prevalent
in 68% of sequences from the Handema et al. cohort, 80.7% in
Cohort A and 64.5% in Cohort B. The high prevalence of this
Table 3. Prevalence of Major ART Mutations Associated with Resistance
to PIs and RTIs in Both Cohorts
Observed prevalence for each resistance mutation (%)
Cohort A, 1998–2002 (N¼ 30) Cohort B, 2005 (N¼ 86) Comparison of prevalence between cohorts, pa
Gene Mutation Class
SDRM
(2008)
SDRM
(2009)
IAS-USA
(2007)
SDRM
(2008)
SDRM
(2009)
IAS-USA
(2007) Cohort A to Cohort B
PR Q58Eb PI 0 —c — 1.16 — — 1.000
RT K103N NNRTI 0 0 0 1.16 1.16 1.16 1.000
RT M184V NRTI 0 0 0 1.16 1.16 1.16 1.000
ap values from the Fisher’s exact test were used to compare the prevalence of mutations between cohorts.
bThe PR mutation Q58E was listed as a major mutation in the SDRM database in 2008. However, Q58E was not designated as a major
mutation by either the SDRM 2009 or the IAS-USA (2007).
c—, No DRAM designated for the respective position.
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mutation in the three cohorts suggests that A316T is a natural
polymorphism in subtype C viruses. However, I323V was
observed only in the Handema et al. cohort and Cohort B in a
prevalence of 4% and 3.8%, respectively. Because all the
Handema et al. cohort and Cohort B samples containing the
I323V mutation also had the A316T mutation, these data in-
dicate that these ART-naive individuals also harbor viruses
that are resistant to maraviroc. To analyze the presence of
resistance against vicriviroc, mutations recently reported
from an in vitro study and from a clinical trial were included in
the analysis,12,28 with the positions of each of these mutant
amino acids based on the HXB2 reference strain.
Not all these resistance mutations were observed in the
sequences from these two studies. For instance, although
K305R was reported by both studies, R315Q was observed
only by Ogert et al.28 and T320R and G321E were reported
only by Tsibris et al.12 When analyzing the prevalence of these
mutations in the Handema et al. cohort and Cohorts A and B,
the mutation R315Q was observed at a prevalence >95% in
the three cohorts and is likely to be a natural polymorphism
for subtype C in Zambia. Interestingly, a similar number of
mutations associated with vicriviroc resistance was observed
in Cohort B (K205R, R315Q, and G321E), Cohort A (K205R,
R315Q, and G321E), or the Handema et al. cohort (K305R,
R315Q, and T320R), and similar frequencies of these muta-
tions were observed in the three cohorts (Table 4). These
mutations were observed in a prevalence range of 0–4% in the
Handema et al. cohort, 0–7.7% in Cohort A, and 0–6.3% in
Cohort B. Because no signature resistance mutations for vi-
criviroc have been identified to date,12 the prevalence of
combinations of vicriviroc partial mutations K305/R315Q,
K305/T320R, and R315Q/G321E was also analyzed. The
prevalence range of these combined mutations was 0–4% in
the Handema et al. cohort, 0–7.7% in Cohort A, and 0–5.06% in
Cohort B.
The different combinations of mutations associated with
resistance to both maraviroc and viriviroc were also analyzed.
The four combinations observed were A316T (maraviroc)þ
K305/R315Q (vicriviroc), A316T (maraviroc)þR315Q (vicri-
viroc), A316T/I323V (maraviroc)þR315Q (vicriviroc), and
A316T (maraviroc)þR315Q/G321E (vicriviroc). An align-
ment of the V3 region of sequences in Cohort A and B-
containing combination of mutations is shown in Fig. 2. Both
the maraviroc mutation A316T and the vicriviroc mutation
R315Q were present in each of these combinations and the
prevalence of the A316TþR315Q combination was 68% for
the Handema et al. cohort, 80.7% for Cohort A, and 58.2% for
Cohort B. On the other hand, the other three combinations
Table 4. Prevalence of Resistance-Associated Mutations Associated with Entry
Inhibitors in Both Cohorts
a
Observed prevalence for each
resistance mutation (%)
Comparison of prevalence
between cohorts, pb
Handema,c
2000
(N¼ 25)
Cohort A,
1998–2002
(N¼ 26)
Cohort B,
2005
(N¼ 79)
Handemac to
Cohort A
Handemac to
Cohort B
Cohort A to
Cohort B
Complete
resistance
Partial
resistance
Maraviroc11
A316T 68 80.7 64.5 0.3487 0.8136 0.1487  þ
I323V 4 0 3.8 0.4902 1.0000 0.5727  þ
A316T/I323Va 4 0 3.8 0.4902 1.0000 0.5727 þ 
Vicriviroc12,22
K305R12,22 4 7.7 6.33 1.0000 1.0000 1.0000  þ
S306P22 0 0 0 N.O.d N.O. N.O.  þ
R315Q12 100 100 98.7 N.O. 1.0000 0.5727  þ
F318I22 0 0 0 N.O. N.O. N.O.  þ
T320R22 4 0 0 0.4902 0.2404 N.O.  þ
G321E22 0 3.8 1.26 1.0000 1.0000 0.4357  þ
K305R, R315Q 4 7.7 5.06 1.0000 1.0000 1.0000  þ
R315Q, T320R 4 0 0 0.4902 0.2404 N.O.  þ
K305R, T320R 4 0 0 0.4902 0.2404 N.O.  þ
K305R, R315Q,
T320R
0 0 0 N.O. N.O. N.O.  þ
R315Q, G321E 0 3.8 1.26 1.0000 1.0000 0.4357  þ
Maravirocþ vicriviroc
A316TþK305R,
R315Q
4 3.8 1.26 1.0000 0.5657 1.0000  þ
A316TþR315Q 68 80.7 58.22 0.3487 0.8116 0.1464  þ
A316T/I323Vþ
R315Q
4 0 3.8 0.4902 1.0000 0.5727 þ/ þ/
A316TþR315Q,
G321E
0 3.8 1.26 1.0000 1.0000 0.4357  þ
aMost of these mutations confer partial resistance; only A316T/I323V has been demonstrated to confer complete resistance to maraviroc.
bp values from the Fisher’s exact test were used to compare the prevalence of mutations between cohorts.
cHandema et al.8
dN.O., no observations.
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were observed at a prevalence range of 0–4% in the Handema
et al. cohort, 0–3.8% in Cohort A, and 1.3–3.8% in Cohort B. No
significant differences were observed when comparing the
prevalence of these mutations between cohorts.
Our study did have some limitations. First, due to the low
prevalence of major mutations in both the cohorts the sample
size may not have been large enough to detect a significant
change. Second, since direct sequencing was employed in this
study, only those mutations present at levels 20% of each
sample viral population were detected.29 Third, because it is
not possible to accurately determine exactly how long the
individuals in our cohorts were actually infected with HIV,
even though they were all asymptomatic, we cannot exclude
the possibility that mutations may have been gained or lost
between the initial infection and the time of sampling.
In summary, most of the mutations observed are natural
polymorphisms characteristic of HIV-1 subtype C. No sig-
nificant differences were observed when comparing drug
resistance-associated mutations and polymorphisms present
in the pol and env of these two cohorts. However, a trend
toward an increase in the number of minor, borderline, or
partial resistance mutations as well as the presence of major
or complete resistance mutations was observed after the
availability of ART in Zambia. The presence of primary
mutations conferring resistance to NRTIs and NNRTIs in
Cohort B indicates that the transmission of drug resistance
FIG. 2. Entry inhibitor resistance-associated mutations in the V3 loop of ART-naive individuals infected with HIV subtype
C. This alignment includes sequences containing a combination of mutations. (A) Three of the 26 env sequences analyzed
from Cohort A contained combined mutations. (B) A combination of mutations was also observed in 9 of the 79 env
sequences from Cohort B.
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was already occurring even though free ART was im-
plemented only recently in Zambia. It is also possible that
mutations associated with PI resistance, such as the Q58E,
may have occurred in individuals receiving therapy from
private clinics before free ART was available. Our observa-
tions nevertheless raise concern that subtype C viruses in
Zambia have a tendency to increase in DRAMs as well as
resistance to ART.
Moreover, we have observed that most of the subtype C
Env sequences harbor natural polymorphisms against entry
inhibitors. These findings are significant because the high
prevalence of these mutations in the population may affect the
efficiency of CCR5 entry inhibitors for the treatment of
Zambian patients infected with HIV-1 subtype C. Whether
this is true for subtype C in other African nations needs to be
determined. In addition, because all the vicriviroc mutations
have been reported to confer partial resistance, further studies
with a larger cohort are needed to determine which individual
mutations or combinations confer complete resistance against
vicriviroc.
Sequence Data
Sequences are available under GenBank accession numbers
GQ427085–GQ427110 (Cohort A env C2V4), GQ427111–
GQ427140 (Cohort A pol), GQ433720–GQ433801 (Cohort B
env C2V4), and GQ433802–GQ433893 (Cohort B pol).
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